|
orphan diseases
|
4
|
Resverlogix Corp.
|
Jun 30, 2018 10:57PM
|
|
Re: orphan diseases
|
8
|
Resverlogix Corp.
|
Jul 01, 2018 03:13PM
|
|
Re: We're back on the buy-in list for Jul 05 2018
|
2
|
Resverlogix Corp.
|
Jul 05, 2018 11:11PM
|
|
Re: orphan diseases
|
2
|
Resverlogix Corp.
|
Jul 05, 2018 11:45PM
|
|
Re: Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
|
4
|
Resverlogix Corp.
|
Sep 04, 2018 12:33PM
|
|
Re: Resverlogix AGM webcast 9/12/2018
|
9
|
Resverlogix Corp.
|
Sep 10, 2018 10:17PM
|
|
Re: RVX buyout projection at $30 US minimum
|
1
|
Resverlogix Corp.
|
Nov 01, 2018 09:54PM
|
|
Re: MACE event rate
|
4
|
Resverlogix Corp.
|
Nov 05, 2018 12:13PM
|
|
apabetalone and colorectal cancer
|
7
|
Resverlogix Corp.
|
Nov 12, 2018 11:12PM
|
|
Re: A New Frontier in CV Risk Reduction for Patients With Type 2 Diabetes
|
7
|
Resverlogix Corp.
|
Dec 17, 2018 11:48AM
|
|
RVX-297 vs RVX-208 for autoimmune indications
|
5
|
Resverlogix Corp.
|
Jan 08, 2019 12:18AM
|
|
Re: RVX-297 vs RVX-208 for autoimmune indications
|
6
|
Resverlogix Corp.
|
Jan 08, 2019 04:24PM
|
|
Re: RVX-297 vs RVX-208 for autoimmune indications
|
3
|
Resverlogix Corp.
|
Jan 09, 2019 01:07PM
|
|
Re: RVX-297 vs RVX-208 for autoimmune indications
|
4
|
Resverlogix Corp.
|
Jan 09, 2019 04:00PM
|
|
Re: RVX-297 vs RVX-208 for autoimmune indications
|
2
|
Resverlogix Corp.
|
Jan 09, 2019 04:16PM
|
|
Re: Sanofi Resverlogix connection?
|
1
|
Resverlogix Corp.
|
Jan 13, 2019 10:54PM
|
|
Re: Contest Tally
|
2
|
Resverlogix Corp.
|
Feb 12, 2019 04:44PM
|
|
Re: The waiting game.....
|
2
|
Resverlogix Corp.
|
Feb 12, 2019 05:09PM
|
|
Re: The waiting game.....
|
5
|
Resverlogix Corp.
|
Feb 12, 2019 06:39PM
|
|
Re: What's going on in Toronto ......
|
2
|
Resverlogix Corp.
|
Feb 25, 2019 03:46PM
|
